Kawasaki disease (KD; MIM 611775) is an acute, inflammatory, and self-limited vasculitis predominantly affecting infants and young children[@b1][@b2][@b3]. Prolonged fever, polymorphous skin rash, and swollen glands, hands, and feet are also observed in these patients. Coronary artery aneurysm(CAA) is the major complication of KD and have made KD the leading cause of acquired cardiovascular complications among children in industrialized countries[@b4]. Much effort has been directed toward decreasing CAA formation in KD. Currently, the only effective evidence-based treatment is administration of aspirin and intravenous immunoglobulin (IVIG) during the acute stage of KD, which abrogates the inflammation and reduces coronary artery damage to less than 5%[@b5]. Although the etiology and pathogenesis of KD remain poorly understood, it is believed that an abnormal and sustained inflammatory stimulus leads to host immune dysregulation in genetically susceptible individuals. During the acute stage, the infiltration of T cells and macrophages and the activation of vascular endothelium cells (ECs) with increased serum proinflammatory cytokines lead to inflammation and damage, with small- and medium-sized vessels along with those of the coronary artery being predominantly affected[@b6][@b7]. The injured vascular tissues show subendothelial edema, vascular damage, gap formation, and fenestration of ECs, all of which contribute to the pathogenesis of this disorder[@b8][@b9]. Therefore, identification of predisposing genetic factors might greatly improve the understanding of this disease and the formation of CAA therein.

Several host genetic factors have been identified that contribute to KD susceptibility through the use of genome-wide screens[@b10][@b11][@b12][@b13][@b14][@b15]. Susceptibility loci related to immune activation, inflammation, apoptosis, and cardiovascular pathology have been reported in Caucasian children with KD[@b10][@b14]. In addition, predisposing loci related to immune activation, inflammation, T cell receptor signaling, regulation of proinflammatory cytokines, and antibody-mediated immune responses have also been described in Asian children with KD[@b12][@b13][@b15][@b16]. It has been further noted through population-based studies in Taiwan that children with KD tend to have higher risks of subsequent allergic susceptibilities including atopic dermatitis (AD), allergic rhinitis (AR), asthma, and urticaria after KD illness[@b17][@b18][@b19][@b20]. These KD predisposing loci might also contribute to determinants of allergic disease with distinct immune phenotypes.

Although the cause of KD remains unknown, many efforts have been made to decrease CAA formation in patients with KD by using aspirin and IVIG treatments. In addition, proposed candidate gene studies for CAA formation in KD have suggested the involvement of genetic factors including *MICB*, *PELI1*, *CASP3*, *CD40*, *MMP-3*, *MMP-12*, HLA-B associated transcript 2, 3, and 5, *ITPR3*, *HLA-E*, *HLA-G*, *ITPKC*, *IL-10*, and angiotensin I converting enzyme (*ACE*) genes[@b11][@b16][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30]. These candidate genes are involved in the immune-regulatory responses and cardiovascular-related pathogenesis that contribute to the susceptibility to and/or formation of CAA in KD. To search for additional loci representing novel mechanisms that might predispose patients with KD to CAA formation, we performed a genome-wide screen to identify novel CAA susceptibility loci in a Han Chinese population in Taiwan, evaluated the relationships between clinical characteristics and aneurysm formation in patients and selected loci, and functionally characterized the associated genes to determine their potential as regulators of proinflammatory cytokine expression in vascular ECs.

Results
=======

Summary data for the newly identified loci associated with CAA formation in Taiwanese Kawasaki disease
------------------------------------------------------------------------------------------------------

To identify the susceptibility gene loci associated with KD related CAA complications, we performed chi-square tests for allelic and genotypic comparisons under the dominant model in a Han Chinese population with KD residing in Taiwan. Stratification of patients for CAA according to either the right or the left coronary artery identified a dilation diameter ≥3 mm in children younger than 5 years of age, or ≥4 mm in older children[@b35][@b31]. As shown in [Table S1](#S1){ref-type="supplementary-material"}, significant clinical factors associated with KD CAA formation were fever duration (*p* \< 0.0001) and time of first IVIG treatment (days after the first day of fever) (*p* \< 0.0001). After adjusting for these potential factors by using multivariate regression analyses, significant associations from genome-wide association tests were observed ([Fig. 1](#f1){ref-type="fig"}). A total of 203 single nucleotide polymorphisms (SNPs) that reached *p* \< 0.005 in the genome-wide screen of KD with CAA versus without CAA are shown in [Table S2](#S1){ref-type="supplementary-material"}. From these, we selected the top 100 SNPs (that reached *p* \< 0.003) for possible pathway mapping and further functional validation. We explored possible functional relationships between the 100 SNP-related genes by using the Ingenuity Pathway Analysis (IPA) Knowledge Base ([Table 1](#t1){ref-type="table"}). The IPA network analysis identified a single cluster of 35 genes that included 26 associated genes discovered in this study ([Fig. 2](#f2){ref-type="fig"}). From among these we selected 4 genes, *KCNQ5*, *PLCB1*, *PLCB4*, and *PLCL1*, for further functional characterization according to the criteria that at least two SNPs were identified in the GWAS study from the same gene and that their *p* values reached *p* \< 5 × 10^−4^ ([Table 1](#t1){ref-type="table"}).

Effect of *KCNQ5*, *PLCB1*, *PLCB4*, and *PLCL1* knockdown on *IL-1*, *IL-6,* and *IL-8* proinflammatory cytokine mRNA expression
---------------------------------------------------------------------------------------------------------------------------------

EC injury and inflammation are some of the major characteristics of the development of KD[@b25]. When ECs were stimulated with pathogenic mediators such as lipopolysaccharide (LPS), the stimulated cells were shown to trigger inflammatory signals to increase permeability and leukocyte recruitment[@b32]. In this study, we examined 4 genes, *KCNQ5*, *PLCB1*, *PLCB4*, and *PLCL1*, for their effect on proinflammatory cytokine mRNA expression by silencing them using siRNA ([Fig. 3](#f3){ref-type="fig"} and [Supplementary Fig. S1](#S1){ref-type="supplementary-material"}) in an LPS-induced endothelial cell inflammation model. Among them, *PLCB1* showed the most significant inhibition of *IL-1 beta*, *IL-6*, and *IL-8* expression. These results suggest that *PLCB1* might regulate endothelial cell inflammation via interference with proinflammatory cytokine expression. This is the first study to report that *PLCB1* is a regulator of vascular inflammation and thus its use might be beneficial for many inflammatory diseases associated with endothelial dysfunction.

Plasma levels of phospholipase C (PLC) and the effect of a PLC inhibitor on *IL-1*, *IL-6*, and *IL-8* proinflammatory cytokine mRNA expression
-----------------------------------------------------------------------------------------------------------------------------------------------

The molecular interactions between PLCB1, PLCB4, and PLC and their effect on proinflammatory cytokine production have been previously investigated[@b33][@b34][@b35][@b36][@b37]. Furthermore, as shown in [Fig. 2](#f2){ref-type="fig"}, the PLCB1-PLC interaction might then regulate the NF-κB complex and affect the production of IL-1, IL-6, and IL-8 proinflammatory cytokines. Plasma PLC concentrations were therefore measured in 96 patients with KD by enzyme-linked immunosorbent assays (ELISAs). Phospholipase C levels in plasma samples from patients with KD were analyzed in relation to *PLCB4/B1* (rs6140791) genotypes ([Fig. 4A](#f4){ref-type="fig"}). In patients with KD, those with CC+CG genotypes appeared to have significantly higher plasma levels of PLC than did those with the GG genotype (CC+CG: 738.7; GG: 549.7; *p* = 0.029). To investigate the effects of PLC inhibitor application on the IL-1, IL-6, and IL-8 proinflammatory cytokine production via the NF-κB complex, the PLC inhibitor (U73122) was used to treat ECs. LPS was then added to induce an EC inflammation model. As shown in [Fig. 4B--D](#f4){ref-type="fig"}, U73122 mediated significant inhibition of *IL-1 beta*, *IL-6*, and *IL-8* expression. Thus, the PLC inhibitor U73122 might regulate EC inflammation via interference with proinflammatory cytokine expression.

*PLCB4/B1* polymorphism and CAA severity
----------------------------------------

From our genome wide analysis, we identified one locus as being associated with CAA, the rs6140791 SNP located between the *PLCB4* and *PLCB1* genes on chromosome 20p12. As shown in [Table 1](#t1){ref-type="table"}, the frequencies of the CC+CG genotypes of this polymorphism were significantly higher in patients with KD with CAA than in those without CAA (OR = 2.861; 95% CI = 1.597--5.125; *p* = 4.08 × 10^−4^). The distributions of the CC+CG genotypes of this SNP were further analyzed according to CAA severity ([Fig. 5](#f5){ref-type="fig"}). As compared with the KD without CAA group, the risk genotypes (CC+CG) of the significantly associated SNP rs6140791 were found to be enriched in the patients with KD with CAA remission between 2--12 months and also in those with giant CAA.

Discussion
==========

Genome-wide association analysis has enabled the discovery of novel genetic loci that contribute to KD susceptibility[@b10][@b11][@b12][@b13][@b14][@b15]. More recently, genetic susceptibility for the development of CAA formation has also been investigated using candidate gene analyses[@b11][@b16][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30]. These studies have provided us with a preliminary genetic architecture of KD as well as of CAA formation therein. In the present work, we identified susceptibility loci that might contribute to CAA formation in Taiwanese patients with KD and identified one locus (rs6140791), located between the *PLCB4* and *PLCB1* genes, which showed likely contribution through functional analysis. Individuals carrying the CC+CG genotypes of this polymorphism had higher levels of plasma PLC; furthermore, we also observed a greater number of individuals with the CC+CG genotypes in the group of KD patients with CAA than in those without CAA. In addition, we showed that the effect of LPS-induced EC inflammation was highly significantly inhibited by application of siPLCB1 or PLC inhibitor, suggesting that the *PLCB4/B1* genes might play a role in the CAA pathogenesis of KD.

Genome-wide association studies have been applied in children with KD to identify CAA-associated loci[@b38][@b39]. Lin and colleagues performed a genome-wide association study using patients with KD with extremely large aneurysms (diameter \> 8 mm; n = 64) and those without CAA (n = 70)[@b38]. Their work led to the discovery that the genetic variant rs2833195 in the intron of the *TIAM1* gene was associated with the development and severity of CAA in KD. Their results implied that the TIAM1 protein might be required for chemokine-induced T-cell migration and the lymphocyte infiltration into the arterial wall during the acute stage of KD. In addition, Kim and colleagues found that the genetic variant rs17136627 of the *KCNN2* gene was associated with CAA development in KD also by using patients with KD with only very large aneurysms (diameter \> 5 mm; n = 17) and those without CAA (n = 123) for their KD CAA genome-wide screen[@b39]. They suggested that the as the *KCNN2* gene is highly expressed in arterial myocytes it might be associated with heart disease such as arrhythmias. However, the biological role of the *KCNN2* gene in KD pathogenesis remains to be elucidated. Because of limited sample numbers and lack of functional analyses, the significance of these newly identified CAA-associated loci remain inconclusive. In the present work, we analyzed genome-wide screen data generated from a larger sample size. We also adjusted the potential genetic factors for clinical factors such as fever duration and the time of first IVIG use as these factors have been previously reported to be associated with CAA formation in KD[@b40][@b41][@b42]. From this analysis, we identified CAA susceptibility loci in a Taiwanese cohort of patients with KD; we further characterized these novel genes, and identified *PLCB4* and *PLCB1* as important regulators of proinflammatory cytokine expression in vascular ECs.

Patients with KD tend to have abnormal serum lipid profiles and are associated with important abnormalities in lipid metabolism[@b43][@b44][@b45][@b46]. Serum lipid profiles such as triglycerides, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels have been used as predictors of atherosclerosis, and have also been associated with cardiovascular diseases. As previously reported, patients with KD and coronary abnormalities have decreased HDL-C levels compared with those without such aneurysms[@b45][@b46]. Furthermore, another study reported that the levels of total cholesterol, LDL-C, and apolipoprotein B were higher in patients with KD and coronary abnormalities than in those without such aneurysms[@b44]. In the present work, we found 100 susceptible loci that were associated with KD CAA. Among them, we observed that a single cluster of 35 genes was associated with the top networks, i.e., embryonic development, nervous system development and function, organ development, and lipid metabolism by using the Ingenuity Pathway Analysis (IPA) Knowledge Base ([Table S3](#S1){ref-type="supplementary-material"}). Our KD CAA genome-wide findings suggest that these potential CAA-associated gene variants might affect not only the severity of vasculitis during the acute stage of KD, but also might be related to lipid metabolism after KD illness. Children with these potential gene susceptibility variants might have high lipid profiles and arterial stiffness subsequent to KD, indicating an increased risk for cardiovascular disease.

In the present work, we chose 4 lipid metabolism associated genes, *KCNQ5*, *PLCB1*, *PLCB4*, and *PLCL1*, from among the highlighted gene cluster for further functional investigation. We used an LPS-induced EC inflammation model and knockdown of *KCNQ5*, *PLCB1*, *PLCB4*, and *PLCL1* by siRNA and found that these genes might regulate EC inflammation via interference with proinflammatory cytokine expression. Of these, the *PLCB1* gene showed the most significant inhibition. Consistent with this, our results also showed that EC inflammation was inhibited by using a PLC inhibitor as well. PLCB1 is expressed in cardiomyocytes, and overexpression of this protein causes cardiomyocyte hypertrophy. For synovial fibroblasts, macrophages, dendritic cells, and ECs, inflammation induced by thrombin, bradykinin, LPS, porphyromonas gingivalis, or advanced glycation end products has been shown to be affected by PLC inhibitors, suggesting that PLC might also be involved in NF-κB activation and proinflammatory cytokine release in inflammatory diseases[@b33][@b34][@b35][@b36][@b37]. The SNP rs6140791 is located between the *PLCB4* and *PLCB1* genes. KD patients carrying the CC+CG genotypes of this polymorphism appeared to have higher plasma PLC levels than did those with the GG genotype. In addition, the KD with CAA group tended to have more individuals with CC+CG genotypes than did the group without CAA. The CC+CG genotypes were further enriched in the patients with KD who exhibited CAA remission between 2--12 months and also in the patients with KD and giant CAA, suggesting that individuals carrying CC+CG genotypes might have higher expression levels of PLC. In turn, people with higher levels of PLC might have more severe inflammations and more potential to develop CAA in KD. This is the first study to report that *PLCB1* is a regulator of vascular inflammation and to suggest that its use might therefore be beneficial for the management of inflammatory diseases associated with endothelial dysfunction.

KD is the leading cause of acquired cardiovascular diseases among children with a possible underlying pathology of immune-mediated vasculitis[@b1][@b47]. Endothelial cell injury and inflammation play important roles in the development of KD as well as in CAA formation[@b25]. When ECs were induced by pathogenic mediators including LPS, the cells were shown to activate inflammatory signals to increase permeability and leukocyte recruitment[@b32]. In this study, functional investigation suggested that RNA silencing of *PLC* genes or pharmacologic inhibition of PLC downregulated EC inflammation. The PLC gene, *PLCB1*, consists of 36 exons and localizes to 20p12. *PLCB1* codes for the PLC beta 1 protein, which represents one of the four PLC beta isoforms (PLC beta 1--4), has two transcript variants comprised of 1216 and 1173 residues that produce different proteins. PLC beta plays important roles in cardiomyocytes, synovial fibroblasts, macrophages, dendritic cells, and endothelial cells[@b33][@b34][@b35][@b36][@b37][@b48][@b49]. Furthermore, genetic variants in *PLCB4/PLC1* have been significantly associated with several phenotypic traits including levels of apolipoprotein B, cholesterol and HDL, along with body weight, body mass index and stroke ([Table S4](#S1){ref-type="supplementary-material"}). For cardiomyocytes, PLC beta is the immediate downstream target of Gαq, a heterotrimeric G protein that regulates its activation, and hydrolyzes the plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) protein to produce the second messengers inositol 1,4,5-triphosphate (IP3; a regulator of the intracellular calcium response) and diacylglycerol (DAG, an activator of protein kinase C subtypes)[@b50]. Studies have reported that PLC beta might transmit the cardiac hypertrophy signal initiated by Gαq[@b48][@b51]. Our findings are also in agreement with these studies. Our results demonstrated that the effect of LPS-induced EC inflammation was inhibited with the most significant inhibition by using siPLCB1 or a PLC inhibitor, suggesting that PLCB1 might be involved in EC inflammation, a possibility that has important implications for understanding the pathogenesis of immune-mediated vascular diseases.

In conclusion, we have identified a gene locus that is associated with a genetic predisposition to the development of CAA in KD in Taiwanese children of Han Chinese ethnic background. Functional analysis also supports the possibility that *PLCB1* might predispose patients with KD to CAA formation.

Methods
=======

Study population
----------------

All experiments were performed in accordance with the relevant guidelines and regulations. This study was approved by the Human Studies Committee of China Medical University Hospital. Written informed consent was obtained from the participants or their parent or legal guardian. Two hundred and sixty-two unrelated patients fulfilling the KD diagnostic criteria were identified and enrolled from the Children's Hospital of China Medical University in Taichung, Taiwan[@b25][@b42][@b52][@b53][@b54]. There were 76 patients with KD with CAA complications and 186 patients with KD without CAA complications, with an average age at onset of 1.86 ± 1.78 and 1.70 ± 1.51 years old, respectively ([Table S1](#S1){ref-type="supplementary-material"}). All patients were diagnosed according to KD criteria[@b55][@b56], including fever lasting 5 days or more and at least 4 of the following symptoms: (1) changes in extremities (e.g., erythema, edema, or desquamation), (2) bilateral conjunctivitis, (3) polymorphous rash, (4) cervical lymphadenopathy, and (5) changes in the lips or oral cavity (e.g. pharyngeal erythema, dry/fissured or swollen lips, or "strawberry tongue"). All patients with KD received IVIG treatment and had regular echocardiographic examinations during the 1-year follow-up period. Echocardiographic examinations were completed during the acute stage, at 2 and 6 months after onset, and once per year thereafter. CAA was identified when either the right or the left coronary artery showed a dilated diameter ≥3 mm in children younger than 5 years of age, or ≥4 mm in older children[@b31][@b55], regardless of whether the CAA went into remission between 2--12 months after KD illness. Only Han Chinese individuals, who account for 98% of Taiwanese residents, were recruited. The ethnic background was assigned based on the results of self-reported questionnaires. The characteristics and clinical profiles of patients with KD enrolled in the study are summarized in [Table S1](#S1){ref-type="supplementary-material"}. Statistically significant differences were observed for fever duration (*p* \< 0.0001), first time of IVIG treatment (days after the first day of fever) (*p* \< 0.0001), and efficacy of the first IVIG treatment (*p* = 0.002). No significant differences were observed in our study for laboratory test results obtained at the acute stage within 24 h before IVIG treatment and for KD status within 3--7 days after IVIG treatment.

Genotyping and quality control
------------------------------

Genomic DNA was extracted from patient blood according to standard protocols by using the Qiagen Genomic DNA Isolation Kit (Qiagen, Taichung, Taiwan). For the genome-wide screen, each sample was genotyped by the National Genotyping Center at Academia Sinica (Taipei, Taiwan) using the Affymetrix Genome-Wide Human SNP Array 6.0, which contains a total of 906,600 SNPs, according to the manufacturer's procedure. Genotype data were quality controlled and SNPs were excluded for further analysis if (1) only one allele appeared in patients; (2) the total call rate was less than 95%; (3) the total minor allele frequency was less than 5%; or (4) the SNP significantly departed from Hardy-Weinberg equilibrium proportions (*p* \< 0.05).

Statistical analysis
--------------------

Data were expressed as indicated for continuous variables ([Table S1](#S1){ref-type="supplementary-material"}). Chi-squared tests were used to identify differences in categorical variables, and ORs and 95% CIs were calculated for the factors under consideration. Genotypes were obtained by direct counting followed by forward stepwise multivariate regression analyses for adjusting clinical factors (fever duration and first time of IVIG use) ([Table 1](#t1){ref-type="table"}). All statistical analyses were performed using SPSS v12.0 for Windows (IBM, Armonk, NY, USA).

Cells
-----

HUVECs (BCRC Number: H-UV001) were grown in 90% GIBCO medium 199 (Life Technologies) with 25 U/mL heparin (Sigma, St. Louis, MO, USA), 30 μg/mL endothelial cell growth supplement (Millipore, Billerica, MA, USA) adjusted to contain 1.5 g/L sodium bicarbonate + 10% fetal bovine serum and 100 U/mL penicillin/streptomycin.

Short Interfering RNA
---------------------

siRNA targeting transcripts for *KCNQ5*, *PLCB1*, *PLCB4*, and *PLCL1* (5′--3′; siKCNQ5: duplex 1, GGGCAAAUCACAUCAGAUA; duplex 2, CAACACAGGUGCCAAUUAG; duplex 3, GACAUGUUGUGUAGAAUUA; duplex 4, GGGAGGCACUUGGAAAUUA; siPLCB1: duplex 1, GAAGAUAACAGAAGCUAAA; duplex 2, GCAAUUGGCUGCUUUGACA; duplex 3, GAUGAUGACUCAACUAUUG; duplex 4, CAACAGAAAUCGUUUGUGA; siPLCB4: duplex 1, GUAAUUGUCUCGAAAUGAA; duplex 2, GAGAAUAGCUGUGUAUGAU; duplex 3, CAAGAAAGGUAUUGAACUU; duplex 4, CCACUAAUAUCCAUCCAUA; siPLCL1: duplex 1, GCACAGAAGCGCAGUCUUU; duplex 2, GGUAAUGGCUCAACAGAUG; duplex 3, GAAGAAAGUUCGGGAAUAU; duplex 4, GUAGGGAGCUCUCUGAUUU) were purchased from Invitrogen (Carlsbad, CA, USA), as were the non-targeting siRNA scrambled controls (siNC: duplex 1, AUGAACGUGAAUUGCUCAA; duplex 2, UAAGGCUAUGAAGAGAUAC; duplex 3, AUGUAUUGGCCUGUAUUAG; duplex 4, UAGCGACUAAACACAUCAA).

Endothelial cell inflammation assay
-----------------------------------

To measure endothelial cell inflammation, HUVECs were aliquoted in 6-well plates. Cells were transfected with the desired siRNAs or siNCs as controls using Lipofectamine 2000 (Invitrogen). The transfected cells were then treated with 50 μg/mL LPS for another 24 h. Cellular RNA extraction and real-time reverse transcription (RT)-PCR analyses were performed as described below.

Real-time RT-PCR
----------------

Cellular RNAs were isolated using a QIAamp® RNA Mini Kit according to the manufacturer's instructions (Qiagen, Valencia, CA, USA). RNAs were eluted in 60 μL buffer, and real-time TaqMan RT-PCR assays were used to determine the siRNAs knock-down efficiency. The primers used for quantitative PCR (qPCR) amplification were as follows: *KCNQ5*, forward: 5′- AGGGGAAGCATCAAGCAGTA -3′ and reverse: 5′- CGCACTCGCTCCTTAAAACT -3′; *PLCB1*, forward: 5′- GTGGGAGACACGCCAAAG -3′ and reverse: 5′- GGCCCATACACCACTGTGA -3′; *PLCB4*, forward: 5′- CGGGAAGTCTTCGGTAGAAA -3′ and reverse: 5′- CCCAGCAGTCAAGTTCAACA -3′; *PLCL1*, forward: 5′- TCACTTGTGATGAAAGACAGCTT -3′ and reverse: 5′- GAGAAACCGGCTCTCTTGAA -3′; *IL-1 beta*, forward: 5′-TACCTGTCCTGCGTGTTGAA-3′ and reverse: 5′-TCTTTGGGTAATTTTTGGGATCT -3′; *IL-6*, forward: 5′- CAGGAGCCCAGCTATGAACT -3′ and reverse: 5′- GAAGGCAGCAGGCAACAC -3′; *IL-8*, forward: 5′- GAGCACTCCATAAGGCACAAA -3′ and reverse: 5′- ATGGTTCCTTCCGGTGGT -3′. Reverse transcription was performed in a 10 μL reaction mixture consisting of 2 μL RNA template, 1 μL RT primer mix, 1 μL dNTP mix (10 mm each), and 6 μL RNA/DNAse-free water at 65 °C for 5 min. Next, a reaction mixture of 4 μL 5 × MMLV buffer, 0.8 μL MMLV enzyme, and 5.2 μL RNA/DNAse-free water was added to each RNA sample. Reverse transcription reactions were performed at 42 °C for 60 min. cDNA was amplified by PCR in a 20 μL reaction mixture containing 5 μL cDNA, 10 μL, 2 × Mastermix, 1 μL primer/probe mix, and 4 μL RNA/DNAse-free water. Real-time TaqMan RT-PCR conditions were 95 °C for 10 min, and 50 cycles of 95 °C for 10 s, and 60 °C for 60 s. RNA levels were detected using a 7900HT Fast Real-Time PCR System (Life Technologies, Carlsbad, CA, USA).

*In vivo* and in *vitro* PLC analysis
-------------------------------------

Serum PLC levels in patients with KD were assessed using a Human Phospholipase C (PLC) Enzyme-linked Immunosorbent Assay (ELISA) kit (Cat. No: E0788Hu) obtained from Shanghai Crystal day Biotech Co., Ltd. (Shanghai, China) according to manufacturer instruction (<http://www.bt-laboratory.com/admin/upload/201212139414181958.pdf>). For determination of the *in vitro* effects of the PLC inhibitor U73122 (Cat. No: U 6756, Sigma), HUVEC cells were treated with10 μM for 24 h at 37 °C followed by 50 μg/mL LPS for another 24 h., followed by qRT-PCR analysis.
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![Genome-wide screening results.\
Manhattan plot for the SNPs on autosomal chromosomes, obtained using the chi-square test under a dominant model. The red and blue horizontal lines indicate the threshold of the genome-wide screen (*p* \< 1 × 10^−5^) and the cutoff level for the top 203 SNPs used for the following functional studies (*p* \< 0.005), respectively.](srep14762-f1){#f1}

![Putative gene network derived from Ingenuity Pathway Analysis (IPA) software.\
IPA network analysis identified a single cluster of 35 genes that includes 26 associated genes discovered in this study. The lines between genes represent known interactions (solid lines represent direct interactions; dashed lines represent indirect interactions). Each gene is displayed using various shapes that represent the functional class of the gene product, as indicated in the legend.](srep14762-f2){#f2}

![Effect of *KCNQ5*, *PLCB1*, *PLCB4*, and *PLCL1* down-regulation on *IL-1*, *IL-6*, and *IL-8* proinflammatory cytokine mRNA expression.\
HUVEC cells were transfected with siKCNQ5, siPLCB1, siPLCB4, and siPLCL1 or siNC for 24 h application of LPS for an additional 24 h. *IL-1beta* (**A**), *IL-6* (**B**), and *IL-8* (**C**) mRNA expression levels were quantified by RT-qPCR. Data represent means ± SD for three independent experiments.](srep14762-f3){#f3}

![Plasma levels of phospholipase C (PLC) and the effect of a PLC inhibitor on *IL-1*, *IL-6*, and *IL-8* proinflammatory cytokine mRNA expression.\
(**A**) Detection of PLC in plasma from patients with KD. PLC concentrations in plasma samples from 96 patients with KD are shown in relation to genotypes. *P* values were determined by student's t test. B) HUVEC cells were treated with PLC inhibitor for 24 h followed by treatment with LPS for another 24 h. *IL-1beta* (**B**), *IL-6* (**C**) and *IL-8* (**D**) mRNA expression levels were quantified by RT-qPCR. Data represent means ± SD for three independent experiments.](srep14762-f4){#f4}

![Distribution of the rs6140791 risk genotype frequency in the *PLCB4*/*B1* gene according to CAA severity.\
CAA was classified as an \>3 or \>4 mm increase in coronary artery diameter in children under or over 5 years of age during the first 2 months of KD diagnosis, respectively[@b31][@b55]. CAA severity grade: KD without CAA indicates patients with no CAA complications; KD with CAA (remission between 2--6 months) indicates patients with CAA, but who showed remission between 2--6 months after KD illness; KD with CAA (remission between 6--12 months) indicates patients with CAA, but who showed remission between 6--12 months after KD illness; KD with CAA (giant CAA) indicates patients with giant CAA (≥8 mm) or severe stenosis or occlusion. The genotypes of rs6140791 are shown according to CAA severity, and the number of patients in each category are indicated.](srep14762-f5){#f5}

###### Association results for the 100 SNPs in GWAS analysis of KD with CAA and without CAA.

  **SNP**       **Chr.**   **Cytoband**   **Position**[a](#t1-fn1){ref-type="fn"}   **Gene**[b](#t1-fn2){ref-type="fn"}        **Gene Relationship**         **Genotype**    **P**     **OR**
  ------------ ---------- -------------- ----------------------------------------- ------------------------------------- ---------------------------------- -------------- ---------- --------
  rs11210499       1          p34.2                      41624031                                 HIVEP3                               intron                    C/T        4.65E-04   0.3494
  rs11264793       1          q23.1                      157677735                              FCRL4/FCRL3               upstream/downstream/UTR-3/intron       A/T        3.21E-04   2.946
  rs7549100        1          q23.1                      157688051                                 FCRL3                               intron                    A/G        4.74E-04   2.826
  rs10801121       1          q31.2                      192509743                                 RGS1                         upstream/downstream              A/G        3.80E-04   2.972
  rs7537542        1          q32.1                      199271032                          LOC100131234/NR5A2                    upstream/intron                A/G        2.91E-04   0.3178
  rs12095873       1          q32.1                      202818914                          LOC641515/KDM5B-AS1                 upstream/downstream              C/T        0.001924   2.649
  rs6693436        1           q41                       219112207                               LOC643723                             intron                    C/T        0.001407   3.045
  rs12119303       1           q41                       219141207                               LOC643723                             intron                    G/T        9.90E-04   3.193
  rs4846532        1           q41                       219156014                               LOC643723                             intron                    A/G        9.90E-04   3.193
  rs6541205        1           q41                       219160887                               LOC643723                             intron                    C/T        9.90E-04   3.193
  rs10746384       1           q41                       219202204                                LYPLAL1                              intron                    A/G        6.19E-04   3.373
  rs1568804        1           q41                       219217862                            RNU5F-1/LYPLAL1                   upstream/downstream              A/G        9.11E-04   3.216
  rs6704354        1           q41                       219220546                            RNU5F-1/LYPLAL1                   upstream/downstream              C/T        9.11E-04   3.216
  rs6670457        1           q41                       219229084                            RNU5F-1/LYPLAL1                   upstream/downstream              A/G        7.16E-04   3.335
  rs11118243       1           q41                       219233066                            RNU5F-1/LYPLAL1                   upstream/downstream              C/T        7.16E-04   3.335
  rs16848112       1          q42.13                     227747048                                SNAP47                               intron                    C/T        1.64E-05   4.075
  rs6674275        1          q42.13                     227748758                                SNAP47                               intron                    C/T        1.64E-05   4.075
  rs12064596       1          q42.13                     227756257                                SNAP47                               intron                    A/G        1.91E-05   4.033
  rs12064154       1          q42.13                     229146328                              RAB4A/RHOU                      upstream/downstream              C/T        5.98E-04    2.76
  rs2345493        2          p24.2                      18110934                               KCNS3/RDH14                      downstream/intron               G/T        2.12E-05   4.971
  rs2345496        2          p24.2                      18135374                               KCNS3/RDH14                      downstream/intron               A/G        1.60E-04   4.047
  rs10202102       2          p13.3                      68784021                                ARHGAP25                              intron                    C/T        3.65E-04   3.656
  rs10174913       2          q14.1                      116017590                              DDX18/DPP10                     upstream/downstream              A/C        5.01E-04   3.945
  rs16831039       2          q33.1                      199144083                              PLCL1/SATB2                          downstream                  C/T        8.51E-05    3.31
  rs1376584        2          q33.1                      199144170                              PLCL1/SATB2                          downstream                  C/T        8.51E-05    3.31
  rs1901321        2          q33.1                      199148856                              PLCL1/SATB2                          downstream                  A/G        5.42E-05   3.472
  rs921465         2          q33.1                      199150704                              PLCL1/SATB2                          downstream                  A/C        7.39E-05   3.391
  rs1868913        2          q33.1                      199162581                              PLCL1/SATB2                          downstream                  A/T        8.51E-05    3.31
  rs1901323        2          q33.1                      199162766                              PLCL1/SATB2                     downstream/upstream              A/T        8.51E-05    3.31
  rs10931853       2          q33.1                      199163235                              PLCL1/SATB2                     downstream/upstream              C/T        8.51E-05    3.31
  rs6730991        2          q33.1                      199165025                              PLCL1/SATB2                     downstream/upstream              A/G        8.51E-05    3.31
  rs16831114       2          q33.1                      199166663                              PLCL1/SATB2                     downstream/upstream              C/T        9.34E-05   3.288
  rs1584661        2          q33.1                      199170501                              PLCL1/SATB2                     downstream/upstream              C/T        8.51E-05    3.31
  rs6742079        2          q33.1                      199173285                              PLCL1/SATB2                     downstream/upstream              A/G        8.51E-05    3.31
  rs6717968        2          q33.1                      199193218                              PLCL1/SATB2                          downstream                  C/T        8.51E-05    3.31
  rs10804088       2          q33.1                      199203328                              PLCL1/SATB2                          downstream                  A/G        8.51E-05    3.31
  rs1376591        2          q33.1                      199203436                              PLCL1/SATB2                          downstream                  C/T        8.51E-05    3.31
  rs4338918        2          q33.1                      199208128                              PLCL1/SATB2                          downstream                  A/T        8.51E-05    3.31
  rs6796318        3          p22.3                      32260293                                  CMTM8                               intron                    A/G        7.32E-04   3.415
  rs4132830        3          p22.3                      32273890                                  CMTM8                               intron                    C/T        0.002041   3.058
  rs3821595        3          p12.3                      78619433                                  ROBO1                               intron                    A/T        0.001671   0.3807
  rs6807510        3          p12.3                      78630434                                  ROBO1                               intron                    C/T        0.001684   0.3808
  rs6793657        3          q21.3                      127185449                         PLXNA1/TPRA1/C3orf56                 downstream/upstream              C/T        3.73E-04   0.2914
  rs13072025       3          q21.3                      127199552                         PLXNA1/TPRA1/C3orf56                      downstream                  A/T        7.91E-04   0.3694
  rs11923216       3          q21.3                      127205138                             PLXNA1/TPRA1                          downstream                  C/T        7.91E-04   0.3694
  rs2411265        4           q12                       52777311                          ERVMER34-1/LOC152578                       upstream                   A/G        0.00185    2.517
  rs17613967       4           q12                       52779752                          ERVMER34-1/LOC152578                       upstream                   G/T        0.001459   2.571
  rs10028567       4           q12                       52791409                                LOC152578                             intron                    C/T        0.001459   2.571
  rs4862161        4          q35.1                      183349528                            CLDN24/CDKN2AIP                   upstream/downstream              C/T        4.35E-04   0.2932
  rs17608672       5          p15.33                      2645450                                IRX4/IRX2                      upstream/downstream              C/T        0.001117   3.916
  rs9313144        5          p15.32                      6132052                            KIAA0947/FLJ33360                  downstream/upstream              C/T        4.19E-05   0.2777
  rs12514641       5          q23.1                      120075328                             PRR16/FAM170A                    upstream/downstream              C/T        9.74E-04   0.3764
  rs10045387       5          q23.1                      120076291                             PRR16/FAM170A              upstream/downstream/UTR-3/intron       A/G        6.86E-04   0.3629
  rs356486         5          q31.2                      139705517                              PSD2/CXXC5                   upstream/downstream/intron          C/G        0.002847   2.624
  rs17668965       5          q35.1                      169590225                                CCDC99                               intron                    A/G        2.09E-04   3.032
  rs2317217        6          p25.3                       796483                              EXOC2/LOC285768                   upstream/downstream              A/C        2.05E-04   0.3254
  rs7757332        6          p25.3                       800495                              EXOC2/LOC285768                   upstream/downstream              C/T        0.001312   0.3595
  rs688176         6          p25.2                       4067874                             PRPF4B/FAM217A                     downstream/intron               C/T        1.51E-04   0.3233
  rs593291         6          p25.2                       4068481                                 FAM217A                        UTR-3/intron/exon               A/C        1.56E-04   0.3187
  rs595413         6          p25.2                       4068931                                 FAM217A                     missense/intron/cds/exon           C/T        1.32E-04   0.3189
  rs2783063        6          p25.2                       4080643                            C6orf201/FAM217A                          intron                    G/T        5.27E-04   0.3568
  rs11755877       6          p25.2                       4081942                           C6orf201/FAM217A /                         intron                    C/G        3.50E-04   0.347
  rs101418         6          p25.2                       4083037                            C6orf201/FAM217A                          intron                    C/T        1.38E-04   0.3213
  rs662834         6          p25.2                       4083154                            C6orf201/FAM217A                          intron                    C/G        3.50E-04   0.347
  rs634114         6          p25.2                       4086685                            C6orf201/FAM217A                          intron                    C/G        1.38E-04   0.3213
  rs707991         6          p25.2                       4097677                                C6orf201                              intron                    A/G        1.04E-04   0.3145
  rs16896290       6           q12                       65118594                                   EYS                                intron                    G/T        8.21E-04   3.272
  rs841531         6           q12                       65196436                                   EYS                                intron                    C/T        6.85E-04   3.196
  rs10485313       6           q12                       65210760                                   EYS                                intron                    A/G        6.03E-04   3.241
  rs539248         6           q12                       65218659                                   EYS                                intron                    A/T        6.57E-04   3.291
  rs4142063        6           q12                       65259036                                   EYS                                intron                    G/T        2.30E-04   3.609
  rs6915695        6           q12                       65269380                                   EYS                                intron                    A/T        2.30E-04   3.609
  rs4991400        6           q13                       73210711                              KCNQ5/KHDC1L                      downstream/intron               A/T        3.83E-04   0.3496
  rs6453655        6           q13                       73210829                              KCNQ5/KHDC1L                      downstream/intron               A/T        3.83E-04   0.3496
  rs41420446       7          p15.1                      28177760                                  JAZF1                               intron                    A/G        4.70E-04   0.2814
  rs1868651        7          p14.1                      37601817                              ELMO1/GPR141                           upstream                   G/T        5.35E-04   0.3538
  rs7795852        7           q34                       140300704                         LOC100134229/SLC37A3                  downstream/intron               A/G        8.94E-05   3.768
  rs6993670        8           p22                       18871430                                  PSD3                                intron                    A/G        1.88E-05   4.184
  rs10119687       9          q22.33                     97710546                                XPA/FOXE1                      upstream/downstream              A/G        8.14E-05   3.555
  rs7849782        9          q31.1                      101664981                                GRIN3A                               intron                    C/G        7.54E-06   0.2482
  rs912745         10         q26.11                     117738648                            EMX2/RAB11FIP2                         downstream                  C/T        2.43E-04   4.945
  rs217756         11         p15.1                      16784612                            C11orf58/PLEKHA7                    downstream/intron               G/T        9.84E-05   4.557
  rs520289         11         q23.3                      117479421                                DSCAML1                              intron                    A/G        5.12E-04   0.345
  rs926150         12         p11.22                     28087892                              PTHLH/CCDC91                           upstream                   C/G        7.79E-04   0.3701
  rs470393         12         q24.33                     128972744                                GLT1D1                               intron                    C/T        4.00E-04   3.818
  rs12590437       14         q21.1                      37977886                        FOXA1/SSTR1/LOC100652860                 upstream/intron                A/T        9.31E-06   4.009
  rs10144855       14         q22.2                      54745523                                 SAMD4A                               intron                    C/G        1.34E-04   3.159
  rs17774131       16         q22.1                      69469883                           CYB5B/MIR1538/NFAT5                 downstream/upstream              C/G        0.001114   2.674
  rs12598083       16         q24.1                      86397391                           LOC732275/FOXF1-AS1                 upstream/downstream              C/G        2.90E-05   3.615
  rs11082212       18         q12.3                      40803209                             LOC647946/KC6 /                   upstream/downstream              A/G        6.96E-05   4.123
  rs1431301        18         q12.3                      40818374                             LOC647946/KC6 /                   upstream/downstream              A/G        6.96E-05   4.123
  rs2313647        18         q12.3                      40819127                             LOC647946/KC6 /                   upstream/downstream              C/T        6.96E-05   4.123
  rs17756653       18         q12.3                      40820189                             LOC647946/KC6 /                   upstream/downstream              C/T        6.96E-05   4.123
  rs323585         18         q12.3                      40865874                             LOC647946/KC6 /                   upstream/downstream              A/G        1.08E-04   3.906
  rs9951264        18         q12.3                      44457712                               SYT4/SETBP1                     upstream/downstream              G/T        0.00149    0.3937
  rs1030583        18         q21.33                     62068449                                  PIGN                                intron                    C/G        1.88E-04   3.526
  rs11659253       18          q23                       77895725                               SALL3/GALR1                     upstream/downstream              C/T        2.52E-04   3.343
  rs6140791        20         p12.3                       8906575                               PLCB4/PLCB1                  upstream/downstream/intron          C/G        4.08E-04   2.861
  rs4299396        20         p12.3                       8934667                               PLCB4/PLCB1                  upstream/downstream/intron          A/T        2.12E-04   3.057
  rs16995415       20         p12.3                       8935154                               PLCB4/PLCB1                  upstream/downstream/intron          A/G        2.72E-04   2.962

Association results are ordered by the chromosome, cytoband, and position.

SNP, single nucleotide polymorphism; CAA, KD patients with coronary artery aneurysm; OR, odds ratio.

^a^Chromosome positions are based on NCBI GRCh38 version.

^b^Defined as the gene containing the SNP or the closest genes (within 100 kb up- and downstream) to the SNP.
